Skip to main content
. Author manuscript; available in PMC: 2010 Jun 19.
Published in final edited form as: Immunity. 2009 Jun 4;30(6):875–887. doi: 10.1016/j.immuni.2009.05.005

Figure 5. Nlrp3A350V/+/creT BMDC drive an inflammatory T cell phenotype.

Figure 5

(A) Tamoxifen-treated BMDC from Nlrp3A350V/+/creT and WT mice were treated with LPS, and stained for CD40, OX40L, and MHC class II receptor. (B–I) BMDC were plated with OT II naïve T cells and OVA antigen under Th1, Th2, or Thl7 cell polarizing conditions, or left unpolarized. (B–D) FACS analysis of intracellular IFNγ and IL-17. (E–I) Luminex analysis of culture supernatants for IFNγ, IL-17, IL-5, and IL-4.